谷歌研究团队提出了一种新型的隐私保护合成数据生成算法CTCL，能够在保证隐私的前提下自动生成高质量的合成数据。这项技术不仅减少了计算负担，还提高了数据生成的质量和效率。 近日，谷歌研究人员在ICML 2025会议上展示了他们的最新成果——一种名为CTCL（Data Synthesis with ConTrollability and ...

First-of-its kind tool to guide HCPs on what to consider when staging patients with Mycosis Fungoides and Sézary Syndrome ...

In August 2025, Dren Bio announced a Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics ...

Soligenix Inc. (NASDAQ: SNGX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 70+ brands within the Dynamic Brand Portfolio @ IBN ( InvestorBrandNetwork), a ...

NetworkNewsAudio announces the Audio Press Release (APR) titled “Late-Stage Pipeline Wins Boost Investor Confidence in ...

Prescient Therapeutics (ASX:PTX) has topped up its $6.9 million SPP with a $3 million placement to accelerate its oncology pipeline. ... Read More The post Prescient Therapeutics takes cap raise to $9 ...

In terms of numbers, CTCL affects around 31,000 people in the U.S. and approximately 38,000 people in Europe. For patients, the high unmet need represents a significant burden.

As the American population gets older, chronic and rare diseases are becoming a significant healthcare issue, particularly ...

The safety and preliminary efficacy of BI-1808 monotherapy are currently being evaluated in Part A of the ongoing Phase 2a (NCT04752826) study in patients with T-cell lymphomas, including CTCL.